ASMI reassures on NSAIDs
June 11, 2010
THE Australian Self-Medication
Industry has added its voice in
response to the Danish study of the
use of popular pain relievers (PD
yesterday), saying that NSAIDs
“continue to play an important role
in short-term pain relief for the
majority of consumers”.
ASMI executive director, Juliet
Seifert, said it was important to
note that the pain relievers looked
at in the study were supplied on
prescription and hence often taken
in higher doses, as well as for
longer periods than recommended
for OTC use - an average of 14
days in the study.
The Danish review was also
unable to identify if there was a
pre-existing cardiovascular
condition or other risk factors, and
also didn’t identify the reason for
which the NSAIDs were being
prescribed, Seifert said.
The report also noted that “use of
low-dose ibuprofen and diclofenac
was associated with a decrease in
risk of cardiovascular death”.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Jun 10To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Jun 10
